GLP-1 & Incretin Science

What Is Maridebart Cafraglutide? Antibody Meets Peptide

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Maridebart cafraglutide, formerly AMG 133 and known as MariTide, is a bispecific molecule: a fully human monoclonal antibody that antagonises the GIP receptor, conjugated through amino-acid linkers to two GLP-1 receptor agonist peptides. It blocks the receptor tirzepatide activates.

Key facts

Former code
AMG 133
Format
Antibody-peptide conjugate (bispecific)
GIPR action
Antagonist (blocking antibody)
GLP-1R action
Agonist (two conjugated peptides)
Antibody type
Fully human monoclonal
First reported
Nature Metabolism 2024 (PMID 38316982)
Phase 2 readout
NEJM, 4 September 2025
Dosing interval
Once monthly
Status
Investigational (no authorisation)

An unusual molecular format

Almost everything else in this field is either a peptide or a small molecule. MariTide is neither: it is a monoclonal antibody with peptides chemically attached. The antibody half blocks the GIP receptor; the two conjugated GLP-1 analogue peptides agonise the GLP-1 receptor. One molecule, two opposite kinds of pharmacology, at two different receptors.

Why build it this way

Antibodies are large and long-lived, with half-lives measured in weeks rather than days, and they are excellent at blocking a receptor with high specificity. Peptides are good agonists but clear quickly. Conjugating them exploits each format for what it does best: antibody for durable antagonism, peptide for agonism, with the antibody's long half-life carrying the whole construct. The practical consequence is dosing intervals longer than weekly.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What the Phase 1 data reported

The 2024 Nature Metabolism paper described a randomised, double-blind, placebo-controlled Phase 1 study in participants with obesity, reporting an acceptable safety and tolerability profile alongside pronounced dose-dependent weight reduction. Phase 1 is a small, early setting and its purpose is safety and dose-finding rather than establishing efficacy.

The premise it rests on

MariTide exists because a body of evidence suggested blocking GIPR, not activating it, is the useful direction when combined with GLP-1 agonism. That is the direct opposite of tirzepatide's design premise. Both programmes have produced weight reduction, which is the GIP paradox in its sharpest form. Two well-resourced development efforts built on contradictory readings of the same receptor, neither obviously wrong.

What is not yet known

Whether the reduction is durable, how it compares head-to-head against approved dual agonists, and whether the tolerability advantage the antagonist premise predicts actually materialises at scale. It holds no marketing authorisation in any jurisdiction and is not available outside clinical trials.

The Phase 2 readout

Jastreboff and colleagues published the Phase 2 trial in the New England Journal of Medicine on 4 September 2025, under the title once-monthly maridebart cafraglutide for the treatment of obesity. The dosing interval is the detail worth holding onto: monthly rather than weekly, which follows from the format. An antibody circulates for weeks because it is large enough to escape renal filtration and is recycled by the neonatal Fc receptor, so conjugating GLP-1 peptides to one gives them the antibody’s persistence rather than their own.

Frequently asked questions

Is MariTide a peptide?

Partly. It is an antibody with two GLP-1 agonist peptides conjugated to it, so it is neither a conventional peptide drug nor a small molecule.

Why would blocking GIPR help?

The leading hypothesis is improved tolerability of the co-administered GLP-1 agonist, allowing more GLP-1 signalling before adverse effects limit dosing. This remains a hypothesis.

Is it approved anywhere?

No. It is investigational and holds no marketing authorisation.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.